| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Andrew E Lietz last filed a Form 4 in April 2016, as Director at SFES. The filings on record cover 2 companies. Andrew E Lietz's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 2,157 shares of APH. The APH filings lean toward selling, a net 10,425 shares.
Andrew E Lietz has 13 Form 4 filings on record from May 2013 to April 2016, across 2 companies: Director at Safeguard Scientifics (SFES), 2015–2016; Director at Amphenol (APH), 2013–2015.
The 22 reported transactions were 13 option or other derivative awards, 3 stock awards, 2 open-market purchases and 2 option exercises, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 2 purchases worth about $50K and 1 sale worth about $500K.
The largest open-market purchase was 1,400 shares of SFES at an average $18.01 on July 29, 2015, about $25K.
The only open-market sale was 10,425 shares of APH at an average $48.00 on October 24, 2014, about $500K.
Shares as reported in the last Form 4 for each company; the most recent is from April 2016. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.